Retosiban
Retosiban is a drug that is classified as an oxytocin receptor antagonist. It was developed by GlaxoSmithKline for the management of preterm labor.
History[edit]
Retosiban was first synthesized by GlaxoSmithKline in the early 21st century. The drug was developed as a potential treatment for preterm labor, a condition that affects approximately 10% of all pregnancies worldwide.
Mechanism of Action[edit]
Retosiban works by blocking the action of oxytocin, a hormone that stimulates uterine contractions. By inhibiting the oxytocin receptor, Retosiban can potentially delay or prevent the onset of labor.
Clinical Trials[edit]
Several clinical trials have been conducted to evaluate the safety and efficacy of Retosiban. In Phase II trials, the drug was found to be well-tolerated and showed promising results in delaying preterm labor. However, further studies are needed to confirm these findings and to determine the optimal dosing regimen.
Potential Applications[edit]
In addition to its potential use in preterm labor, Retosiban may also have applications in other conditions that involve oxytocin, such as postpartum hemorrhage, dysmenorrhea, and certain psychiatric disorders.
See Also[edit]
